You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
再鼎醫藥藥(09688.HK):與Seagen就藥物訂立合作和許可協議
再鼎醫藥(09688.HK)公布,其全資附屬公司再創醫藥與Seagen訂立合作和許可協議,據此,公司與Seagen同意合作開發及商業化TIVDAK(tisotumab vedotin)。根據該協議,集團自Seagen獲得於內地、香港、澳門及台灣地區開發及商業化TIVDAK的獨家授權。 根據該協議的條款,公司將向Seagen支付3,000萬美元的預付款,另加於達到指定的開發及註冊里程碑後最高合共7,800萬美元的開發,及註冊里程碑付款及於達到指定的銷售里程碑後最高合共1.85億美元的銷售里程碑付款。Seagen亦將有權根據許可區域內許可產品的年度銷售淨額按中十位數至低二十位數的分級百分比率收取若干特許權使用費。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account